These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 34254405)
1. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Ramakrishnan N; Lijffijt M; Green CE; Balderston NL; Murphy N; Grillon C; Iqbal T; Vo-Le B; O'Brien B; Murrough JW; Swann AC; Mathew SJ Depress Anxiety; 2021 Nov; 38(11):1108-1119. PubMed ID: 34254405 [TBL] [Abstract][Full Text] [Related]
2. A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Lijffijt M; Green CE; Balderston N; Iqbal T; Atkinson M; Vo-Le B; Vo-Le B; O'Brien B; Grillon C; Swann AC; Mathew SJ Front Psychiatry; 2019; 10():846. PubMed ID: 31920733 [No Abstract] [Full Text] [Related]
3. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029 [TBL] [Abstract][Full Text] [Related]
4. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442 [TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Agbo F; Bui KH; Zhou D J Clin Pharm Ther; 2017 Oct; 42(5):539-546. PubMed ID: 28474366 [TBL] [Abstract][Full Text] [Related]
8. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol. Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663 [TBL] [Abstract][Full Text] [Related]
9. Randomized, Placebo-Controlled Trial of the Angiotensin Receptor Antagonist Losartan for Posttraumatic Stress Disorder. Stein MB; Jain S; Simon NM; West JC; Marvar PJ; Bui E; He F; Benedek DM; Cassano P; Griffith JL; Howlett J; Malgaroli M; Melaragno A; Seligowski AV; Shu IW; Song S; Szuhany K; Taylor CT; Ressler KJ; Biol Psychiatry; 2021 Oct; 90(7):473-481. PubMed ID: 34275593 [TBL] [Abstract][Full Text] [Related]
10. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. Heresco-Levy U; Vass A; Bloch B; Wolosker H; Dumin E; Balan L; Deutsch L; Kremer I Int J Neuropsychopharmacol; 2009 Oct; 12(9):1275-82. PubMed ID: 19366490 [TBL] [Abstract][Full Text] [Related]
11. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients. van Zuiden M; Frijling JL; Nawijn L; Koch SBJ; Goslings JC; Luitse JS; Biesheuvel TH; Honig A; Veltman DJ; Olff M Biol Psychiatry; 2017 Jun; 81(12):1030-1040. PubMed ID: 28087128 [TBL] [Abstract][Full Text] [Related]
12. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Mitchell JM; Bogenschutz M; Lilienstein A; Harrison C; Kleiman S; Parker-Guilbert K; Ot'alora G M; Garas W; Paleos C; Gorman I; Nicholas C; Mithoefer M; Carlin S; Poulter B; Mithoefer A; Quevedo S; Wells G; Klaire SS; van der Kolk B; Tzarfaty K; Amiaz R; Worthy R; Shannon S; Woolley JD; Marta C; Gelfand Y; Hapke E; Amar S; Wallach Y; Brown R; Hamilton S; Wang JB; Coker A; Matthews R; de Boer A; Yazar-Klosinski B; Emerson A; Doblin R Nat Med; 2021 Jun; 27(6):1025-1033. PubMed ID: 33972795 [TBL] [Abstract][Full Text] [Related]
13. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331 [TBL] [Abstract][Full Text] [Related]
14. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD. Kanaan RA; Oliver G; Dharan A; Sendi S; Maier A; Mohebbi M; Ng C; Back SE; Kalivas P; Berk M Psychiatry Res; 2023 Sep; 327():115398. PubMed ID: 37540942 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Guo J; Zhou D; Grimm SW; Bui KH Xenobiotica; 2015 Mar; 45(3):244-55. PubMed ID: 25259653 [TBL] [Abstract][Full Text] [Related]
16. Effects of oxytocin administration on fear-potentiated acoustic startle in co-occurring PTSD and alcohol use disorder: A randomized clinical trial. Stauffer CS; Morrison TE; Meinzer NK; Leung D; Buffington J; Sheh EG; Neylan TC; O'Donovan A; Woolley JD Psychiatry Res; 2022 Feb; 308():114340. PubMed ID: 34983010 [TBL] [Abstract][Full Text] [Related]
18. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Mitchell JM; Ot'alora G M; van der Kolk B; Shannon S; Bogenschutz M; Gelfand Y; Paleos C; Nicholas CR; Quevedo S; Balliett B; Hamilton S; Mithoefer M; Kleiman S; Parker-Guilbert K; Tzarfaty K; Harrison C; de Boer A; Doblin R; Yazar-Klosinski B; Nat Med; 2023 Oct; 29(10):2473-2480. PubMed ID: 37709999 [TBL] [Abstract][Full Text] [Related]
19. MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. Ching TH; Williams MT; Wang JB; Jerome L; Yazar-Klosinski B; Emerson A; Doblin R J Psychopharmacol; 2022 Aug; 36(8):974-986. PubMed ID: 35727042 [TBL] [Abstract][Full Text] [Related]
20. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. Rodgman C; Verrico CD; Holst M; Thompson-Lake D; Haile CN; De La Garza R; Raskind MA; Newton TF J Clin Psychiatry; 2016 May; 77(5):e561-5. PubMed ID: 27249080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]